Stocks and Investing
Stocks and Investing
Thu, January 25, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, January 24, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Cory Kasimov Maintained (BMRN) at Buy with Decreased Target to $129 on, Jan 24th, 2018
Cory Kasimov of JP Morgan, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $131 to $129 on, Jan 24th, 2018.
Cory has made no other calls on BMRN in the last 4 months.
There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 0 agree with Cory's Rating of Hold.
These are the ratings of the 6 analyists that currently disagree with Cory
- Liana Moussatos of "Wedbush" Upgraded from Hold to Buy on, Thursday, December 14th, 2017
- M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $119 on, Friday, October 27th, 2017
- Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $105 on, Friday, October 27th, 2017
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $124 on, Thursday, October 19th, 2017
- Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $142 on, Thursday, October 19th, 2017
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017
Contributing Sources